Human medicines European public assessment report (EPAR): Pelmeg, pegfilgrastim, Date of authorisation: 20/11/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Noxafil, posaconazole, Date of authorisation: 25/10/2005, Revision: 38, Status: Authorised

Human medicines European public assessment report (EPAR): Teriflunomide Accord, teriflunomide, Date of authorisation: 09/11/2022, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Byooviz, ranibizumab, Date of authorisation: 18/08/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Pluvicto, lutetium (177Lu) vipivotide tetraxetan, Date of authorisation: 09/12/2022, Revision: 6, Status: Authorised

Human medicines European public assessment report (EPAR): RotaTeq, rotavirus vaccine, live, Date of authorisation: 26/06/2006, Revision: 37, Status: Authorised

Human medicines European public assessment report (EPAR): Stayveer, bosentan monohydrate, Date of authorisation: 24/06/2013, Revision: 16, Status: Authorised

Addendum to EMA/CHMP/CVMP/QWP/17760/2009 Rev 3: Defining the Scope of an NIRS Procedure

Committee for Advanced Therapies (CAT): 17-19 April 2024, European Medicines Agency, Amsterdam, the Netherlands, from 17 April 2024 to 19 April 2024

EU NTC ten year anniversary event, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 30 May 2024, 09:00 (CEST) to 30 May 2024, 16:30 (CEST)